Whether you’re new to GLP-1 medications or seeking better ways to handle your side effects, we are bringing you tips to help you stay on track with your health goals while feeling your best.

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform consumers.

A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.

Recent study held under Dr. Ziyada Al-Aly found that GLP-1 medications can reduce the risk of disease like heart disease and addiction. The reports direct further investigation to reduce anticipated ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy.

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

A RECENT population-based analysis has highlighted potential behavioural side effects associated with Glucagon-like peptide 1 ...

Ozempic and other GLP-1 agonists are helping millions with weight loss but concerns grow over their long-term effects. Recent studies highlight side effects ... using GLP1-RAs for weight loss ...

Discontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting ...

Greater weight loss was linked to lower discontinuation rates, with a 1% reduction in weight lowering the hazard of ...